Glycine Treatment of Prodromal Symptoms

Phase 2

Completed

• Conditions: Schizophrenia
• Interventions: Drug: glycine

• Registration Number: NCT00268749
• Lead Sponsor: Yale University

Brief Summary

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07
• Primary Completion: 2004-11
• Study Completion: 2004-11
• Study First Submitted: 2005-12-20
• Study First Submitted QC: 2005-12-20
• Study First Posted: 2005-12-22
• Status Verified: 2012-03
• Last Update Submitted: 2012-03-28
• Last Update Posted: 2012-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• age 14-35
• meets SIPS criteria for psychosis prodrome

Read More

Exclusion Criteria

• current antipsychotic medication
• more than 4 weeks of antipsychotic medication lifetime

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	glycine	-

Primary Outcome Measures

Name	Time	Method
Scale Of Prodromal Symptoms total score	8 weeks